Madrigal Pharmaceuticals, Inc. Common Stock (MDGL) Price and Market Data

Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to developing innovative therapies for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with significant unmet medical need that can progress to cirrhosis, liver failure, liver cancer, liver transplantation, and premature death. Its treatment, Rezdiffra (resmetirom), is a once-daily oral, liver-directed thyroid hormone receptor beta agonist designed to address key underlying drivers of MASH.